Abstract
The in vivo efficacy of trovafloxacin, intraperitoneally administered as alatrofloxacin (CP-116,517), was assessed and compared with that of erythromycin, alone or in combination with rifampicin, in a model of Legionella pneumophila pneumonia in guinea pigs. Trovafloxacin (5 mg/kg administered as alatrofloxacin once daily for 7 days) gave a survival rate of 100% in infected animals. Clearance of bacteria and of bacteria-induced lesions from lungs was achieved by day 6 post-inoculation. The lungs of trovafloxacin-treated animals remained free of bacteria at day 28 post-challenge. Trovafloxacin proved as effective as erythromycin administered intraperitoneally, but was superior to erythromycin alone. or in combination with rifampicin, when given orally.
MeSH terms
-
Administration, Oral
-
Animals
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / pharmacology
-
Anti-Infective Agents / therapeutic use*
-
Drug Evaluation, Preclinical
-
Drug Therapy, Combination / administration & dosage
-
Drug Therapy, Combination / therapeutic use
-
Erythromycin / administration & dosage
-
Erythromycin / therapeutic use
-
Female
-
Fluoroquinolones*
-
Guinea Pigs
-
Injections, Intraperitoneal
-
Legionella pneumophila / drug effects
-
Legionnaires' Disease / drug therapy*
-
Legionnaires' Disease / microbiology
-
Lung / microbiology
-
Microbial Sensitivity Tests
-
Prodrugs / therapeutic use*
-
Random Allocation
-
Rifampin / administration & dosage
-
Rifampin / therapeutic use
Substances
-
Anti-Infective Agents
-
Fluoroquinolones
-
Prodrugs
-
Erythromycin
-
alatrofloxacin
-
Rifampin